Oscotec’s FDA-approved clinical trials for treatment of acute myeloid leukemia

Published: 2017-04-17 16:26:00
Updated: 2017-04-17 13:38:38

Oscotec(CEO Jung-Geun Kim), a new drug development company, announced on the 13th that it made an agreement since the U.S. Phase 1 clinical trial project of the next-generation new drug candidate(SKI-G-801) for the treatment of acute myeloid leukemia(AML) was selected as the non-clinical/clinical...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.